Loading
When a cancer drug is added to the WHO essential medicines list, the maker should publicly commit to a low price and reliable supply for poorer countries, or the listing is withheld.
Listing on the WHO Model List of Essential Medicines is a reputational asset for manufacturers but carries no obligation. Many listed cancer medicines (trastuzumab, imatinib, rituximab) remained unaffordable or unavailable in most low-income countries for years after listing. The proposal is that the Expert Committee request, as part of the application, a public tiered-price schedule and a minimum supply commitment for low- and lower-middle-income countries, and publish which applicants declined.
Shares Imatinib, Prices and value, Trastuzumab, Most of the world has almost no cancer care.
Shares Global access and affordability roadmap: essential medicines and generics → biosimilars and frugal trials → reliance, pooling and homegrown innovation, Imatinib, Prices and value, Most of the world has almost no cancer care.
Shares Imatinib, Prices and value, Trastuzumab, Most of the world has almost no cancer care.
Shares Global access and affordability roadmap: essential medicines and generics → biosimilars and frugal trials → reliance, pooling and homegrown innovation, Prices and value, Trastuzumab, Most of the world has almost no cancer care.
Shares Global access and affordability roadmap: essential medicines and generics → biosimilars and frugal trials → reliance, pooling and homegrown innovation, Prices and value, Most of the world has almost no cancer care.
Shares Global access and affordability roadmap: essential medicines and generics → biosimilars and frugal trials → reliance, pooling and homegrown innovation, Prices and value, Most of the world has almost no cancer care.
Shares Global access and affordability roadmap: essential medicines and generics → biosimilars and frugal trials → reliance, pooling and homegrown innovation, Prices and value, Trastuzumab.
Shares Global access and affordability roadmap: essential medicines and generics → biosimilars and frugal trials → reliance, pooling and homegrown innovation, Prices and value, Trastuzumab.